FDA Accepts Blenrep Combo Applications for Multiple Myeloma
Ticker: GLAXF · Form: 6-K · Filed: Nov 25, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA, drug-approval, oncology, multiple-myeloma
Related Tickers: GSK
TL;DR
FDA reviewing Blenrep combos for multiple myeloma, big win for GSK if approved.
AI Summary
GSK plc announced on November 25, 2024, that the US FDA has accepted for review new drug applications for Blenrep combinations. These combinations are intended for the treatment of relapsed or refractory multiple myeloma. The submission is supported by data from the Phase III Head-to-H study.
Why It Matters
This FDA acceptance is a significant step towards potentially expanding treatment options for patients with relapsed or refractory multiple myeloma, a serious blood cancer.
Risk Assessment
Risk Level: medium — While FDA acceptance is positive, the ultimate approval and market uptake of these Blenrep combinations remain uncertain.
Key Players & Entities
- GSK plc (company) — Registrant
- Blenrep (drug) — Drug under review
- US FDA (company) — Regulatory body
- November 25, 2024 (date) — Announcement date
- relapsed or refractory multiple myeloma (medical_condition) — Indication for treatment
FAQ
What specific Blenrep combinations are being reviewed by the FDA?
The filing states that 'Blenrep combinations' have been accepted for review, but does not specify the exact combinations being evaluated.
What is the indication for these Blenrep combinations?
The combinations are intended for the treatment of relapsed or refractory multiple myeloma.
What study supports these regulatory submissions?
The regulatory submissions are supported by data from the Phase III Head-to-H study.
When was this announcement made by GSK plc?
The announcement was issued on November 25, 2024.
Where is GSK plc's principal executive office located?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 1,872 words · 7 min read · ~6 pages · Grade level 14.1 · Accepted 2024-11-25 07:13:19
Filing Documents
- a4196n.htm (6-K) — 57KB
- 0001654954-24-014845.txt ( ) — 58KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: November 25, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc